EP Wealth Advisors LLC Buys 2,407 Shares of Olema Pharmaceuticals, Inc.

OLMA Stock  USD 6.72  1.69  20.10%   
About 65% of Olema Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Olema Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Olema Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Olema Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
EP Wealth Advisors LLC grew its stake in Olema Pharmaceuticals, Inc. by 5.2 percent during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 48,655 shares of the companys stock after acquiring an additional 2,407 shares during the period. EP

Read at thelincolnianonline.com
news
  

Olema Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Olema Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Olema Pharmaceuticals Fundamental Analysis

We analyze Olema Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Olema Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Olema Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Employees

Number Of Employees Comparative Analysis

Olema Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Olema Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Olema Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Olema Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Olema Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Olema Pharmaceuticals Related Equities

MOLNMolecular Partners   0.73   
0%
5.0%
OBIOOrchestra BioMed   0.19   
1.0%
0%
FENCFennec Pharmaceuticals   0.49   
3.0%
0%
NVCTNuvectis Pharma   1.49   
11.0%
0%
PEPGPepGen   1.53   
11.0%
0%
CNTACentessa Pharmaceuticals   1.80   
14.0%
0%
PHVSPharvaris   2.01   
15.0%
0%
IRONDisc Medicine   2.52   
19.0%
0%
CGEMCullinan Oncology   2.56   
19.0%
0%
ANTXAN2 Therapeutics   4.52   
35.0%
0%
ERASErasca   5.40   
42.0%
0%
LRMRLarimar Therapeutics   6.00   
46.0%
0%
MLYSMineralys Therapeutics,   6.02   
46.0%
0%
GLUEMonte Rosa   8.46   
65.0%
0%
ZNTLZentalis Pharmaceuticals   10.57   
82.0%
0%
DSGNDesign Therapeutics   11.01   
85.0%
0%
SANASana Biotechnology   12.82   
100.0%
0%

Complementary Tools for Olema Stock analysis

When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
FinTech Suite
Use AI to screen and filter profitable investment opportunities